ZMD.H — ZoomMed Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 237.94% | ||
| Return on Equity | n/a | ||
| Operating Margin | 309.5% | ||
Financial Summary
| Year End 31st May | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | 0.01 | 0.45 | n/a | n/a | -2.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ZoomMed Inc. is a Canada-based company, which builds and operates ZoomMed’s Communication Network, a clinical interoperable information exchange network between physicians and the various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical corporations and private insurers.
Directors
- Yves Marmet CHM
- Marie-Helene Pinard CFO
- Bruno Floriani IND
- Micheline Luneau IND
- Nicolas Matziorinis IND
- Robert Powell IND
- Last Annual
- May 31st, 2023
- Last Interim
- November 30th, 2023
- Incorporated
- February 24th, 2005
- Public Since
- May 18th, 2005
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 135,591,268
- Address
- 9815 Boul. Leduc, Suite 503, BROSSARD, J4Y 0K8
- Web
- https://zoommedcorpo.com/
- Phone
- +1 4506785457
- Auditors
- BDRF CPA Inc
Similar to ZMD.H
Binovi Technologies
TSX Venture Exchange
FluroTech
TSX Venture Exchange
Health Logic Interactive
TSX Venture Exchange
H-Source Holdings
TSX Venture Exchange
Lattice Biologics
TSX Venture Exchange
FAQ
As of Today at 19:24 UTC, shares in ZoomMed are trading at . This share price information is delayed by 15 minutes.
Shares in ZoomMed last closed at and the price had moved by over the past 365 days. In terms of relative price strength the ZoomMed share price has underperformed the Toronto Stock Exchange 300 Composite Index by -6.03% over the past year.
There is no consensus recommendation for this security.
ZoomMed does not currently pay a dividend.
ZoomMed does not currently pay a dividend.
ZoomMed does not currently pay a dividend.
To buy shares in ZoomMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of , shares in ZoomMed had a market capitalisation of .
Here are the trading details for ZoomMed:
- Country of listing: Canada
- Exchange: NEX
- Ticker Symbol: ZMD.H
Based on an overall assessment of its quality, value and momentum ZoomMed is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ZoomMed. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -10.41%.
As of the last closing price of , shares in ZoomMed were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ZoomMed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ZoomMed's management team is headed by:
- Yves Marmet - CHM
- Marie-Helene Pinard - CFO
- Bruno Floriani - IND
- Micheline Luneau - IND
- Nicolas Matziorinis - IND
- Robert Powell - IND